Global Generics Pharmaceutical Company

The global generics market is a critical pillar of modern healthcare, enabling greater access to high-quality, affordable medication to patients across major markets globally.

A combination of originator product’s patent expiries and demographic changes are driving increased demand for and access to affordable, high-quality generics across key markets. Lupin has leveraged this opportunity and is positioned as a leading name in global generics.

Generics and Complex Generics

Lupin’s generics business is built on scale, regulatory strength, and a diversified portfolio across high-burden therapeutic areas. In developed markets, generics continue to be the primary driver of affordability, access, and healthcare sustainability, particularly as populations age and chronic disease prevalence rises.

In the U.S., we continue to be the 3rd largest generics company by filled prescriptions, with an approximately 5% market share. Lupin markets a broad portfolio, with roughly 50 products ranking number one and more then 100 products ranking among the top three in their respective categories.

By leveraging a robust portfolio spanning therapy areas such as diabetes, cardiovascular, respiratory, anti-infectives, anti-TB, and more, Lupin has become a partner of choice and reaches over 60 million lives annually, a considerable portion of the American population.

Across other developed markets, including Europe, Canada, and Australia, Lupin’s generics business continues to scale through differentiated portfolios and strong local execution.

View our Generics Portfolio

Within the generics business, Lupin has centered its strategic growth on complex generics - generics with multi-faceted dynamic constituents, formulations or path of administration, particularly in the inhalation and injectable space.

In the U.S., complex generics will continue to be a driving force, supported by a robust pipeline.

Within the complex generic segment, Lupin has established a strong foothold in both inhalation and injectables, leveraging its differentiated capabilities and robust pipeline to drive growth.

Our Inhalation Business

Lupin’s inhalation portfolio spans across metered-dose inhalers (MDIs), dry-powder inhalers (DPIs), and nasal sprays.

Lupin is also committed to advancing its green propellant inhalers, which have near-zero global warming potential (GWP) to reduce environmental impact while preserving clinical efficacy and safety. These efforts align with evolving regulatory expectations in Europe and Lupin’s commitment to sustainable pharmaceutical innovation.

This focus strengthens Lupin’s position as a responsible leader in complex inhalation generics across regulated markets.

Click here to know more about how Lupin is advancing its respiratory care.

Regional Presence

United States

#3 largest generics company by prescriptions filled
#3 in U.S. generics respiratory sales

Since entering the pharmaceutical generics market in 2003, Lupin has received over 300 FDA approvals and currently markets more than 150 generics products in the U.S.

With deep science-led backing, a robust portfolio, strong customer relationships, and utmost attention to quality, the U.S. remains a critical driver of Lupin’s growth.

Canada

First generic Tolvaptan – affordable access to critical kidney therapy

The Canadian business continues to grow extensively and specializes in gastroenterology, women’s health, and niche and complex generics.

United Kingdom

Luforbec - #1 primary care respiratory brand
230,000+ patients treated monthly for respiratory disorders
Leadership in sustainable inhalers

Lupin Healthcare UK has strengthened its leadership in respiratory care. Luforbec, Lupin’s flagship inhaler, is the top primary care respiratory brand by value and volume, with a large user base highlighting its widespread adoption and trust among prescribers.

Lupin also leads in sustainability through the provision of carbon-neutral inhalers and the development of next-generation, eco-friendly propellants.

EU

Growth led by respiratory, neurology & injectables

Lupin’s EU operations have consistently delivered strong growth, supported by expansion in respiratory, neurology, and injectable portfolios. EU remains a strategically important market, offering diversified opportunities across key therapeutic areas and continued investments in complex segments.

Australia

#4 generics company (Generic Health)
Strategic expansion into complex generics

Australia is a mature, highly regulated pharmaceutical market with a strong generics base. Lupin’s wholly owned subsidiary, Generic Health, is one of the largest generics brand in Australia and has delivered consistent growth over the past five years. Portfolio expansion, operational agility, and entry into new therapy areas continue to strengthen Lupin’s presence in this important developed market.